CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells

Seminars in Cancer Biology

Volumn 20, Issue 6, 2010, Pages 416-423

  Deaglio, Silvia ^a,b   Vaisitti, Tiziana ^a,b   Zucchetto, Antonella ^c   Gattei, Valter ^c   Malavasi, Fabio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Hugef Torino Foundation   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

CD38; Chemotaxis; Chronic lymphocytic leukemia; Homing; Invadosome; Microenvironment; Proliferation

Indexed keywords

ARGININE; CD31 ANTIGEN; CD38 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; STROMAL CELL DERIVED FACTOR 1; TRYPTOPHAN;

AMINO ACID SUBSTITUTION; ANTIGEN EXPRESSION; APOPTOSIS; CELL COMMUNICATION; CELL MOTION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE MODEL; DRUG TARGETING; GENETIC DIFFERENCE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOID ORGAN; MALIGNANT TRANSFORMATION; NONHUMAN; PROGNOSIS; PROMOTER REGION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD38; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; SIGNAL TRANSDUCTION;

EID: 78649774633     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.08.003     Document Type: Review

References (85)

1. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
2. Zenz T., Mertens D., Kuppers R., Dohner H., Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010, 10:37-50.
3. Caligaris-Cappio F., Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?. J Clin Oncol 2008, 26:4497-4503.
4. Damle R.N., Calissano C., Chiorazzi N. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol 2010, 23:33-45.
5. Patten P.E., Buggins A.G., Richards J., Wotherspoon A., Salisbury J., Mufti G.J., et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008, 111:5173-5181.
6. Calissano C., Damle R.N., Hayes G., Murphy E.J., Hellerstein M.K., Moreno C., et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009, 114:4832-4842.
7. Dal-Bo M., Bertoni F., Forconi F., Zucchetto A., Bomben R., Marasca R., et al. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med 2009, 7:76.
8. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008, 26:1544-1552.
9. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
10. Deaglio S., Vaisitti T., Aydin S., Ferrero E., Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006, 108:1135-1144.
11. Matrai Z. CD38 as a prognostic marker in CLL. Hematology 2005, 10:39-46.
12. Malavasi F., Deaglio S., Funaro A., Ferrero E., Horenstein A.L., Ortolan E., et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008, 88:841-886.
13. States D.J., Walseth T.F., Lee H.C. Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38. Trends Biochem Sci 1992, 17:495.
14. 2+ stores: a perspective from cyclic ADP-ribose and NAADP. Curr Mol Med 2004, 4:227-237.
15. Graeff R., Liu Q., Kriksunov I.A., Kotaka M., Oppenheimer N., Hao Q., et al. Mechanism of cyclizing NAD to cyclic ADP-ribose by ADP-ribosyl cyclase and CD38. J Biol Chem 2009, 284:27629-27636.
16. + and its metabolites in cell signaling. Sci Signal 2009, 2:mr1.
17. +: a modulator of immune functions. Innate Immun 2010.
18. Malavasi F, Deaglio S, Zaccarello G, Chillemi A, Audrito V, Serra S, et al. The hidden life of NAD+-consuming enzymes in the endocrine system. J Mol Endocrinol; in press.
19. Deaglio S., Malavasi F. The CD38/CD157 mammalian gene family: an evolutionary paradigm for other leukocyte surface enzymes. Purinergic Signal 2006, 2:431-441.
20. Salmi M., Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol 2005, 5:760-771.
21. Malavasi F., Funaro A., Roggero S., Horenstein A., Calosso L., Mehta K., et al. CD38: a glycoprotein in search of a function. Immunol Today 1994, 15:95-97.
22. Deaglio S., Morra M., Mallone R., Ausiello C.M., Prager E., Garbarino G., et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998, 160:395-402.
23. Deaglio S., Zubiaur M., Gregorini A., Bottarel F., Ausiello C.M., Dianzani U., et al. Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. Blood 2002, 99:2490-2498.
24. Liu Q., Kriksunov I.A., Graeff R., Munshi C., Lee H.C., Hao Q. Crystal structure of human CD38 extracellular domain. Structure 2005, 13:1331-1339.
25. Liu Q., Graeff R., Kriksunov I.A., Jiang H., Zhang B., Oppenheimer N., et al. Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD hydrolase. J Biol Chem 2009, 284:27637-27645.
26. Kumagai M., Coustan-Smith E., Murray D.J., Silvennoinen O., Murti K.G., Evans W.E., et al. Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med 1995, 181:1101-1110.
27. Funaro A., Morra M., Calosso L., Zini M.G., Ausiello C.M., Malavasi F. Role of the human CD38 molecule in B cell activation and proliferation. Tissue Antigens 1997, 49:7-15.
28. Kitanaka A., Ito C., Coustan-Smith E., Campana D. CD38 ligation in human B cell progenitors triggers tyrosine phosphorylation of CD19 and association of CD19 with lyn and phosphatidylinositol 3-kinase. J Immunol 1997, 159:184-192.
29. Deaglio S., Vaisitti T., Billington R., Bergui L., Omede P., Genazzani A.A., et al. CD38/CD19: a lipid raft dependent signaling complex in human B cells. Blood 2007, 109:5390-5398.
30. Zumaquero E., Munoz P., Cobo M., Lucena G., Pavon E.J., Martin A., et al. Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with signaling complexes containing CD81, Hsc-70 and Lyn. Exp Cell Res 2010.
31. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9:581-593.
32. Rodriguez-Alba J.C., Moreno-Garcia M.E., Sandoval-Montes C., Rosales-Garcia V.H., Santos-Argumedo L. CD38 induces differentiation of immature transitional 2 B lymphocytes in the spleen. Blood 2008, 111:3644-3652.
33. Cockayne D.A., Muchamuel T., Grimaldi J.C., Muller-Steffner H., Randall T.D., Lund F.E., et al. Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses. Blood 1998, 92:1324-1333.
34. Lund F.E., Muller-Steffner H., Romero-Ramirez H., Moreno-Garcia M.E., Partida-Sanchez S., Makris M., et al. CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism. Int Immunol 2006, 18:1029-1042.
35. Zupo S., Isnardi L., Megna M., Massara R., Malavasi F., Dono M., et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996, 88:1365-1374.
36. Joshi A.D., Hegde G.V., Dickinson J.D., Mittal A.K., Lynch J.C., Eudy J.D., et al. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 2007, 13:5295-5304.
37. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
38. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194:1625-1638.
39. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
40. Durig J., Nuckel H., Huttmann A., Kruse E., Holter T., Halfmeyer K., et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 2003, 101:2748-2755.
41. Huttmann A., Klein-Hitpass L., Thomale J., Deenen R., Carpinteiro A., Nuckel H., et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 2006, 20:1774-1782.
42. - counter-parts. Leukemia 2006, 20:743-744.
43. Pepper C., Ward R., Lin T.T., Brennan P., Starczynski J., Musson M., et al. Highly purified CD38(+) and CD38(-) sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 2007.
44. Damle R.N., Temburni S., Calissano C., Yancopoulos S., Banapour T., Sison C., et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007, 110:3352-3359.
45. Messmer B.T., Messmer D., Allen S.L., Kolitz J.E., Kudalkar P., Cesar D., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
46. Jaksic O., Kardum-Skelin I., Jaksic B. Chronic lymphocytic leukemia: insights from lymph nodes & bone marrow and clinical perspectives. Coll Antropol 2010, 34:309-313.
47. Deaglio S., Dianzani U., Horenstein A.L., Fernandez J.E., van Kooten C., Bragardo M., et al. Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. J Immunol 1996, 156:727-734.
48. Partida-Sanchez S., Cockayne D.A., Monard S., Jacobson E.L., Oppenheimer N., Garvy B., et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med 2001, 7:1209-1216.
49. Partida-Sanchez S., Goodrich S., Kusser K., Oppenheimer N., Randall T.D., Lund F.E. Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 2004, 20:279-291.
50. Partida-Sanchez S., Iribarren P., Moreno-Garcia M.E., Gao J.L., Murphy P.M., Oppenheimer N., et al. Chemotaxis and calcium responses of phagocytes to formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. J Immunol 2004, 172:1896-1906.
51. Vaisitti T., Aydin S., Rossi D., Cottino F., Bergui L., D'Arena G., et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010, 24:958-969.
52. Deaglio S., Vaisitti T., Aydin S., Bergui L., D'Arena G., Bonello L., et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007, 110:4012-4021.
53. Schroers R., Griesinger F., Trumper L., Haase D., Kulle B., Klein-Hitpass L., et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005, 19:750-758.
54. D'Arena G., Tarnani M., Rumi C., Vaisitti T., Aydin S., De Filippi R., et al. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol 2007, 82:787-791.
55. Kumar A., Humphreys T.D., Kremer K.N., Bramati P.S., Bradfield L., Edgar C.E., et al. CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity 2006, 25:213-224.
56. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826.
57. Zucchetto A., Benedetti D., Tripodo C., Bomben R., Dal Bo M., Marconi D., et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009, 69:4001-4009.
58. Gattei V., Bulian P., Del Principe M.I., Zucchetto A., Maurillo L., Buccisano F., et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008, 111:865-873.
59. Zucchetto A., Tripodo C., Benedetti D., Deaglio S., Gaidano G., Del Poeta G., et al. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38CD49d chronic lymphocytic leukaemia cells. Br J Haematol 2010, 150:111-112.
60. Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., Van den Steen P.E., Hernandez del Cerro M., Roderfeld M., et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010, 17:160-172.
61. Redondo-Munoz J., Ugarte-Berzal E., Garcia-Marco J.A., del Cerro M.H., Van den Steen P.E., Opdenakker G., et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008, 112:169-178.
62. Stefanidakis M., Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 2006, 108:1441-1450.
63. Redondo-Munoz J., Escobar-Diaz E., Samaniego R., Terol M.J., Garcia-Marco J.A., Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006, 108:3143-3151.
64. Ilangumaran S., Borisch B., Hoessli D.C. Signal transduction via CD44: role of plasma membrane microdomains. Leuk Lymphoma 1999, 35:455-469.
65. Nishina H., Inageda K., Takahashi K., Hoshino S., Ikeda K., Katada T. Cell surface antigen CD38 identified as ecto-enzyme of NAD glycohydrolase has hyaluronate-binding activity. Biochem Biophys Res Commun 1994, 203:1318-1323.
66. Shi X., Leng L., Wang T., Wang W., Du X., Li J., et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006, 25:595-606.
67. Gore Y., Starlets D., Maharshak N., Becker-Herman S., Kaneyuki U., Leng L., et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008, 283:2784-2792.
68. Gordin M., Tesio M., Cohen S., Gore Y., Lantner F., Leng L., et al. c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol 2010.
69. Deaglio S., Capobianco A., Bergui L., Durig J., Morabito F., Duhrsen U., et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003, 102:2146-2155.
70. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
71. Deaglio S., Vaisitti T., Bergui L., Bonello L., Horenstein A.L., Tamagnone L., et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005, 105:3042-3050.
72. Deaglio S., Aydin S., Grand M.M., Vaisitti T., Bergui L., D'Arena G., et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med 2010, 16:87-91.
73. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davis Z., Thomas P.W., Stevenson F.K., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99:1023-1029.
74. Willimott S., Baou M., Huf S., Deaglio S., Wagner S.D. Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. Haematologica 2007, 92:1359-1366.
75. Ferrero E., Saccucci F., Malavasi F. The human CD38 gene: polymorphism, CpG island, and linkage to the CD157 (BST-1) gene. Immunogenetics 1999, 49:597-604.
76. Gonzalez-Escribano M.F., Aguilar F., Torres B., Sanchez-Roman J., Nunez-Roldan A. CD38 polymorphisms in Spanish patients with systemic lupus erythematosus. Hum Immunol 2004, 65:660-664.
77. Drummond F.J., Mackrill J.J., O'Sullivan K., Daly M., Shanahan F., Molloy M.G. CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss. J Bone Miner Metab 2006, 24:28-35.
78. Jamroziak K., Szemraj Z., Grzybowska-Izydorczyk O., Szemraj J., Bieniasz M., Cebula B., et al. CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians. Cancer Epidemiol Biomarkers Prev 2009, 18:945-953.
79. Aydin S., Rossi D., Bergui L., D'Arena G., Ferrero E., Bonello L., et al. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?. Blood 2008, 111:5646-5653.
80. Yagui K., Shimada F., Mimura M., Hashimoto N., Suzuki Y., Tokuyama Y., et al. A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with Type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro. Diabetologia 1998, 41:1024-1028.
81. Listi F., Caruso C., Balistreri C.R., Grimaldi M.P., Caruso M., Caimi G., et al. PECAM-1/CD31 in infarction and longevity. Ann N Y Acad Sci 2007, 1100:132-139.
82. Genot E. The endothelial podosome. Med Sci (Paris) 2009, 25:168-174.
83. Saltel F., Daubon T., Juin A., Ganuza I.E., Veillat V., Genot E. Invadosomes: intriguing structures with promise. Eur J Cell Biol 2010.
84. Marchisio P.C., Bergui L., Corbascio G.C., Cremona O., D'Urso N., Schena M., et al. Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes. Blood 1988, 72:830-833.
85. Caligaris-Cappio F., Bergui L., Corbascio G., Tesio L., Malavasi F., Marchisio P.C., et al. Membrane-microfilament interactions in the cells of B-chronic lymphocytic leukemia. Haematol Blood Transfus 1987, 31:195-196.